Fesoterodine fumarate - Overactive bladder (adults)

You are here : Home > Formulary Search > Fesoterodine fumarate - Overactive bladder (adults)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)

Formulations :

Not Specified

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

Guidelines BNF SPC

Restrictions / Comments :

Documentation

Guidelines (Local)

Selection tool for OAB treatments - Nov 2024

Patient resource

Leaflet-for-trial-of-stopping-OAB-drugs - anticholinergics - Mar 24

Webpage

NICE NG123 Urinary-incontinence-and-pelvic-organ-prolapse-in-women

Webpage

NICE Clinical guideline [CG97] : Lower urinary tract symptoms in men: management

Webpage

LUTS in Men - Management of Overactive Bladder - CKS guidance

Webpage

Urinary incontinence in women - CKS guidelines

PAD Profile

ChemicalSubstance :

Fesoterodine fumarate

Indication :

Overactive bladder (adults)

Group Name :

Keywords :

antimuscarinics, OAB, urge incontinence, urinary incontinence, urinary frequency, LUTS, urinary urgency, anticholinergics

Brand Names Include :

Toviaz, Teraleve, Zecatrin

Important Information :

3rd line - for patients requiring more potent treatment

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Overactive bladder (adults)

Supporting Documents :

Other Indications

Below are listed other indications that Fesoterodine fumarate is used to treat.

No records returned.

Other Drugs

Below are listed other drugs that are used to treat Overactive bladder (adults).

Committee Recommendations (2)

06 Mar 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The APC supports patients in trialling a treatment break of their overactive bladder medicines.

A "Leaflet for trial of stopping anticholinergics" can be found in the documents section below.

05 Jul 23 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Fesoterodine is recommended as a 3rd line option in patients who require, and can tolerate, a more potent treatment.

Solifenacin is the 1st line treatment option.

Tolterodine immediate release tablets or Trospium are 2nd line options in patients for whom solifenacin is not suitable.

See Selection Tool for locally agreed OAB treatment options